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Heavy Ion Therapy led to unique treatment options in
certain types of cancer, extending to more challenging
disease entities. However, effects which abrogate treat-
ment success can be active in the patient. For example,
tumors generally induce inflammation and a hypoxic
environment. This leads to cells which are resistant
against direct effects of X-rays and results in a very lim-
ited access by the immune system. Which is disadvan-
tageous, as the immune system was shown to contribute
significantly to radiotherapy success. Therefore, we de-
vised a pharmacological system which is addressing the
resistance against direct effects of radiation and to re-
lieve tumor induced immune suppression. The method
was shown to improve the tumor phenotype and to en-
hance the sensitivity to X-ray- and particle irradiation,
yielding more killed cells, expressing more immune ac-
tivating ligands.
Description of the field
Radiotherapy, Pharmacology and Immune Therapy
evolved in different fields of science, following more
physical, chemical and biological lines of thinking, re-
spectively. However, it has turned out that the immune
system is heavily influencing direct and indirect effects of
radiation. Therefore, we recently argued to transform the
way radiation is interacting with the immune system of the
patient and the tumor pharmacologically.1
Description of the project
Exploiting the recent knowledge about exposure pathways
and molecular hallmarks of the immunogenicity of radi-
ation and drugs, we first combined two pharmacological
entities with radiation. Chloroquine is an established anti
malarial drug even in preventive use, CDDO-Me is an
anti inflammatory synthetic triterpenoid which is in clinical
studies. To further improve the immunological and direct
radiation effects, a combined c-Met / VEGFR2 Inhibitor
(TKI) was added to the combination, which is already ap-
proved for medullary thyroid cancer.
Results
The combination of Chloroquine and CDDO-Me led to
increased surface translocation of the immune relevant
molecules CD95, MHC-I, Rae-1, Calreticulin and TRAIL.
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Adding the TKI further enhanced the pro-apoptotic prop-
erties of the combined treatment in CT26.WT tumor cells.
As apoptotic cells were shown to express more immune
relevant molecules on the surface, increased apoptotic cell
death is thought to be beneficial for the induction of tu-
mor immune responses. This effect of enhanced tumor cell
killing was even more pronounced using carbon ions.
Outlook
Despite this treatment has so far only been tested in vitro by
us, a solid and significantly increasing amount of clinical
and preclinical evidence points to the beneficial effects of
the pharmacological components used for supporting im-
mune therapies. Therefore, it could be envisaged that in a
combined treatment, there is significant translational poten-
tial for use in carbon ion therapy and other radiation based
therapy forms as well.
Figure 1: Increased surface translocation of CD95 and
MHC-I after irradiation under the influence of Chloro-
quine, CDDO-Me and the combination thereof. Note: The
drug effects became pronounced only in irradiated cells
while there was only little change in non-irradiated cells.
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